Resolve Technologies® Introduction

To systematically investigate the crystallization behavior of drug substances, Pharmaterials offers a range of screening platforms all  designed around the properties of the molecule under study as well as the budget and timeframes available to our clients. Since most of the candidate drug substances for screening are in the early stages of drug development (preclinical to phase I clinical trials), our crystallization screening and analytical technology is scaled down to ensure minimise sample use.

With a minimal amount of product (< 5 grams), we can screen a broad and diverse parameter space in a short space of time. Intelligent experimental planning and procedures yield an impressive throughput of at least 200 crystallizations per day. Combined with the initial design of experiments and additional analytical work, the results of a polymorph screen are typically presented 6 weeks after the start of the project.

Additionally, we can grow crystals for fast reliable single crystal structure analysis, giving a clear understanding for patent and regulatory submissions.